PREPARATION OF HYPERIMMUNE SERA FOR SARS-COV-2 VIRUS
Main Article Content
Authors
G.D. Nakhanova
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
O.V. Chervyakova
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
K.A. Shorayeva
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
A.S. Zhakypbek
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
S.U. Moldagulova
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
K.K. Jekebekov
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
Zh.S. Absatova
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
E.A. Shayakhmetov
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
A.D. Omurtay
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
T.I. Baiseit
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
A.K. Nakhanov
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
A.A. Kerimbayev
LLP «Research Institute for Biological Safety Problems» Gvardeysky 080409, Kazakhstan
Abstract
Hyperimmune sera are a primary component of diagnostic test systems utilising enzyme immunoassay to identify specific antibodies against infectious disease pathogens. During diagnostic assay development, hyperimmune sera function as positive controls and enable the generation of standard curves for quantitative measurement of antibody levels. Furthermore, they can be used to assess the sensitivity and specificity of established test systems and to verify novel diagnostic approaches. The objective of this study was to produce hyperimmune serum against SARS-CoV-2. Purified and concentrated virus, in conjunction with adjuvants such as aluminium hydroxide or AddaS03, was employed to immunise animals. Consequently, specific sera exhibiting activity in ELISA at dilutions of 1:1600- 1:3200 and in the diffusion precipitation reaction (DPR) at 1:8–1:32 were acquired. The research demonstrated that the use of concentrated, pure SARS-CoV-2 for animal immunisation, supplemented with adjuvants, is a viable and efficacious approach for generating highly active antibodies.
Keywords
SARS-CoV-2, immunisation, hyperimmune sera, enzyme immunoassay (ELISA), purified virus, adjuvant, AddaS03, aluminium hydroxide
Article Details
References
Drosten S., Gunter S., Praiser V., Werf S., Brodt H. R., Becker S. The phenomenon of novel coronavirus in patients with severe acute respiratory syndrome. // The New England Journal of Medicine. – 2003. – No 348. – рр. 1967–76.
Peiris D., Lai S. M., Poon S. T. Koronavirus as a possible cause of severe acute respiratory syndrome / / Lancet, 2003, – No. 361 –, pp.1319-1325.
Camila B.P., Francislene J., Luis E.R., Norman A., Rafael C., Helena C. COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus // Journal of International Immunology. - 2021. - No. 90. - pp.1-9.
Paltiel, A., Rabinovich, A. "The Road Towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. // Nature Reviews Immunology. - 2020. - Vol. 20, No. 12. - pp.711-722. - DOI: 10.1038 / s41577-020-00476-7.
Severino J., Caroline T., Klarissa M., Renata P., Keith P., Alain K., Lindomar P. Clinical and laboratory diagnosis of SARS-CoV-2, the virus causing COVID-19 // ACS Infectious Diseases. – 2020. – Vol. 6, No 11. – pp. 2319–2336. – DOI: 10.1021/acsinfecdis.0c00274.
Mitra G., Matthias L., Laura L., Manon W., Marina S., Philip V., Silvio S., Annika K., Tran T., Lukas P., Hanspeter S., Jasmine P., Melle H., Nadine E., Nadine S., Corinne G., Patrik Z., Horst P., Simone S., Amanda V., Andres M., Eugenia C., Nicolas R., Gergely T., Veronika M., Bevan S., Volker T., Ronald D. Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wild animals to severe acute respiratory syndrome coronavirus 2 // Emerging Infectious Diseases. – 2021. – Vol. 7. – pp. 46–55.
Afanas'ev E. N., Tyumentseva I. S., Kogotkova O. I., Lyapustina L. V., Zharnikova I. V., Savelyeva I. V., Budyka D. A. Development of new approaches to obtaining hyperimmune sera for the production of medical immunobiological preparations. - 2010. - No. 103. - pp. 67-69.
Alieva E. V. Experience in obtaining immune sera for the production of diagnostic drugs / / Man and his health. - 2008. - No. 1. - p. 11.
Alieva E. V., Tyumentseva I. S., Afanasyev E. N., Lavreshin M. P., Afanasyev N.E., Gorobets E. A., Semircheva A. A., Mironov A. Yu. Experience in obtaining immune serums for the production of diagnostic drugs. 2008, Nо. 1, pp. 11-13.
Kasenov M. M., Orynbayev M. B., Zakarya K., Kerimbayev A. A., Zhugunisov K. D., Sultankulova K. T. and others. Strain "SARSCoV-2 /KZ_Almaty/ 04.2020" of the COVID-19 coronavirus infection virus, used for the preparation of means of specific prevention, laboratory diagnostics and evaluation of the effectiveness of biological protection of vaccines against COVID-19 coronavirus infection / / Patent of the Republic of Kazakhstan No. 34762. - 2020.
Zhugunisov K., Kerimbayev A., Kopeev S., Myrzakhmetova B., Tuyskanova M., Nakhanov A. K., Khairullin B., Orynbayev M., Abduraimov E., Kasenov M., Zakarya K., Kutumbetov L. B. SARS-CoV-2 virus: isolation, cultivation, thermal stability, inactivation and passivation //. The biological series. – 2022. - Vol. 90, No. 1. - pp. 73-89. - DOI: 10.26577/eb. 2022. v90. i1. 07.
Lowry O.H., Rosebrough N.I., Farr A.L. The determination of protein concentration with the Folin phenol reagent // Journal of Biological Chemistry. 1951, vol. 193, pp. 265-275.
Nabieva E. R., Nikolaeva O. N. The neutralization reaction and its use in virology. - 2019. - Vol. 19, No. 2. - pp. 120-130.
Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints // American Journal of Epidemiology. – 1938. – Vol. 27. – pp. 493–497. – DOI: 10.1093/oxfordjournals.aje.a118408.
Bintou A.A., Marcus W.C., Yan L.N., Chee K.M., Justin Jang Hann Chu. Current perspective of antiviral strategies against COVID-19 // ACS Infectious Diseases. – 2020. – № 10. – pp. 1624–1634.
Camila B.P., Francislene J., Luis E.R., Norman A., Rafael C., Helena C. COVID-19 and hyperimmune sera: A feasible plan B to fight against coronavirus // Journal of International Immunology. - 2021. - No. 90. - pp. 1-9.
Sedov V. N., Fedorov V. M. Impact of aluminum and its compounds on the functions of human organs and tissues: a review article. – 2021. – URL: URL.
Marrack P. etc. Toward understanding the adjuvant action of aluminum / / Nature Reviews Immunology. - 2009. - Vol. 9, No. 4. - pp. 287-293.
Morel S. Adjuvant System AS03, containing alpha-tocopherol, modifies the innate immune response and contributes to the improvement of adaptive immunity / / Vaccine. - 2011. - Vol. 29. - p. 2461.
Shi S. etc. Vaccine adjuvants: Understanding the structure and mechanism of adjuvance / / Vaccine. - 2019. - Vol. 37. – p. 3167.